An expert's opinion: Interview with Dr Pablo Moral on the fight against antimicrobial resistance

on November 18, 2026

Dr Pablo Moral is a bioscientist working at GSK Global Health Medicines. As the industrial lead of the EU-funded END2AMR project, a European consortium launched in 2026 to pioneer novel therapies against drug-resistant pathogens, Dr. Moral stands at the forefront of the fight against antimicrobial resistance, one of the major healthcare challenges of our time.


Could you explain what the multi-million-euro initiative END2AMR project aims to achieve and what your specific role involves?

Pablo Moral profilePablo Moral: END2AMR stands for “European Novel Drug Research to Address Microbial Infections and Drug Resistance” and is a cross-border collaborative research project composed of twelve partners, supported by the Innovative Health Initiative (IHI), born with the aim to develop novel therapeutic approaches in the antibiotic sector.

In this consortium, we have both public partners, such as academic institutions, and private partners, such as GSK, across different Work Packages (WP). I deal with Work Package 2 specifically, which evaluates the possibility of using lysins to expand the currently available treatment options for bacterial infections.

Lysins are proteins derived from bacteriophages, viruses that infect bacteria. Their main role is to break down bacterial cell walls and destruct the bacteria in what is known as “lytic death”. Lysins are therefore a promising new antibiotic tool.


What drove the decision to explore lysins, and why does it hold so much promise in the fight against drug-resistant infections?

Pablo Moral: We are inspired by nature, in a way. When we think about antimicrobial resistance (AMR), we need to understand that bacteria are living beings that continue to evolve. Most antibiotics have a limited number of bacterial targets, they act on limited pathways, and most of those are already subject to resistance. It is a sort of race between us and evolution, and innovation is what keeps us going.

If we look at it more broadly, all the work that we do at END2AMR revolves around the idea that we need a wider range of tools to attack bacteria. The more tools we have, the higher chances of contrasting resistant infections. Lysins are being explored as potential addition to these tools.


You mentioned the role of evolution in antimicrobial resistance development. How can research consider this aspect to avoid developing solutions that will become obsolete too quickly?

Pablo Moral: Evolution, which is one of the most fascinating things you can find in nature, and adaptation to the environment cannot be stopped. We cannot halt evolution: we have to assume that it will keep going and bacteria will continue to change. It is a fight that is going to keep happening.

This is why within END2AMR, we focus on new targets and new mechanisms of action that allow us to study and address resistance from very early stages, and to explore innovation from different perspectives.

Of course, the wider response to antimicrobial resistance also needs a broad pipeline of therapeutic and preventive approaches, diagnostics, surveillance and responsible antibiotic use, alongside new treatments. We can't rely on a single solution.


What are the main goals that you have reached so far at END2AMR and what are you most worried or excited about in the upcoming years?

Pablo Moral: We only started working on this project in January this year, but we have already built a interdisciplinary consortium and a diverse portfolio of expertise and opportunities. Every month, even every week, we have meetings across the consortium to discuss our progress. We can discuss science together every day. This is already a big achievement, and I am excited about the opportunity to explore new scientific pathways.

What worries me, on the other hand, is that antimicrobial resistance is not like a tsunami, it is more like a rising sea level. It's slower but it will always keep rising, it will catch up; in fact, it is already affecting patients and health systems around the globe.


Today, 18 November, is European Antibiotic Awareness Day. As a scientist who has spent the last seven years working to tackle antimicrobial resistance, is there a message you would like to share with the community on this occasion?

Pablo Moral: I am grateful for the opportunity to pass on this message: antimicrobial resistance is shaping clinical outcomes and people's lives worldwide, and it is a real problem that will continue to grow. This is why I want to emphasise how important it is that research in this field continues, that funding is not suspended and that we invest in it even more, including in Europe. We need to keep innovation ahead of resistance.

Related article